Published in

Taylor and Francis Group, Scandinavian Journal of Rheumatology, 5(46), p. 335-345, 2016

DOI: 10.1080/03009742.2016.1209550

Links

Tools

Export citation

Search in Google Scholar

Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

Journal article published in 2016 by Bj J. Ejbjerg, Signe Møller Bisgaard ORCID, I. Eshed, K. Hørslev Petersen ORCID, Ml L. Hetland, Ag G. Jurik, H. Thomsen, T. Torfing, K. Stengaard Pedersen, P. Junker, Ns S. Krogh, T. Lottenburger, Ls S. Andersen, Torkell Ellingsen ORCID, H. Skjødt and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objectives To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect. Method In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (